FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309661662> ?p ?o ?g. }

• W4309661662 endingPage "e31873" @default.
• W4309661662 startingPage "e31873" @default.
• W4309661662 abstract "Immune checkpoint inhibitors (ICIs) are currently approved for a variety of cancers and their use is expanding from advanced disease to first-line metastatic and adjuvant therapies. With the wide application of immunotherapy, its adverse reactions are also the object we need to pay attention to. Among its adverse events, immune myocarditis has low morbidity, but a high fatality rate. Simultaneously, the unique biological properties of thymic epithelial tumors (TETs) increase the risk of immune-mediated toxicity.Patient 1 underwent chest computed tomography (CT) in April 2019 due to physical examination, which showed pleural metastasis of thymoma. Tissue puncture under CT guidance revealed type B2 thymoma. First-line chemotherapy with docetaxel combined with nedaplatin was administered, and apatinib was administered as a maintenance therapy after chemotherapy. After a regular review, progression of the disease was observed in April 12, 2021.Patient 2 underwent anterior mediastinal tumor resection on August 2, 2019, due to the completion of the CT examination during myasthenia gravis to suggest a thymic tumor. Postoperative pathology revealed type B3 thymoma. The patient underwent local radiotherapy from October 2019 to November 2019. After irregular reexamination, the patient's condition was stable. Disease progression has been observed in June 2021.Both patients were diagnosed with thymoma.Patient 1 was administered one cycle of gemcitabine, carboplatin, and sintilimab after disease progression. Patient 2 was treated with docetaxel and cisplatin for 2 cycles, and tislelizumab was added in the second cycle.Both patient 1 and patient 2 developed immune myocarditis after one cycle of immunotherapy. The difference was that patient 1 died within a few days. After a few days of active treatment for patient 2, the immune myocarditis did not improve significantly, and the patient chose to give up the treatment and go home. The shocking outcome is that the patient remains alive and stable.Oncologists should be wary of ICI-related myocarditis owing to its early onset, nonspecific symptoms, and fulminant progression, especially when ICIs are used in combination. The patient's cardiac condition should be assessed before administering ICIs." @default.
• W4309661662 created "2022-11-29" @default.
• W4309661662 creator A5046021669 @default.
• W4309661662 creator A5056018285 @default.
• W4309661662 creator A5058340142 @default.
• W4309661662 creator A5060978357 @default.
• W4309661662 creator A5082857859 @default.
• W4309661662 creator A5090366405 @default.
• W4309661662 date "2022-11-18" @default.
• W4309661662 modified "2023-10-18" @default.
• W4309661662 title "Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report" @default.
• W4309661662 cites W1995401688 @default.
• W4309661662 cites W2014182808 @default.
• W4309661662 cites W2043851911 @default.
• W4309661662 cites W2101386197 @default.
• W4309661662 cites W2136847876 @default.
• W4309661662 cites W2166662937 @default.
• W4309661662 cites W2168499787 @default.
• W4309661662 cites W2547133566 @default.
• W4309661662 cites W2614467908 @default.
• W4309661662 cites W2783137027 @default.
• W4309661662 cites W2784751095 @default.
• W4309661662 cites W2789315292 @default.
• W4309661662 cites W2793167197 @default.
• W4309661662 cites W2804734521 @default.
• W4309661662 cites W2891486030 @default.
• W4309661662 cites W2891525212 @default.
• W4309661662 cites W2901191795 @default.
• W4309661662 cites W2951831906 @default.
• W4309661662 cites W2963849817 @default.
• W4309661662 cites W2969985260 @default.
• W4309661662 cites W2972933681 @default.
• W4309661662 cites W2981698704 @default.
• W4309661662 cites W3007666278 @default.
• W4309661662 cites W3013672432 @default.
• W4309661662 cites W3109732135 @default.
• W4309661662 cites W3146004114 @default.
• W4309661662 doi "https://doi.org/10.1097/md.0000000000031873" @default.
• W4309661662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36401466" @default.
• W4309661662 hasPublicationYear "2022" @default.
• W4309661662 type Work @default.
• W4309661662 citedByCount "4" @default.
• W4309661662 countsByYear W43096616622023 @default.
• W4309661662 crossrefType "journal-article" @default.
• W4309661662 hasAuthorship W4309661662A5046021669 @default.
• W4309661662 hasAuthorship W4309661662A5056018285 @default.
• W4309661662 hasAuthorship W4309661662A5058340142 @default.
• W4309661662 hasAuthorship W4309661662A5060978357 @default.
• W4309661662 hasAuthorship W4309661662A5082857859 @default.
• W4309661662 hasAuthorship W4309661662A5090366405 @default.
• W4309661662 hasBestOaLocation W43096616621 @default.
• W4309661662 hasConcept C121608353 @default.
• W4309661662 hasConcept C126322002 @default.
• W4309661662 hasConcept C141071460 @default.
• W4309661662 hasConcept C143998085 @default.
• W4309661662 hasConcept C197934379 @default.
• W4309661662 hasConcept C2776349617 @default.
• W4309661662 hasConcept C2776694085 @default.
• W4309661662 hasConcept C2777701055 @default.
• W4309661662 hasConcept C2778105408 @default.
• W4309661662 hasConcept C2778233292 @default.
• W4309661662 hasConcept C2779159893 @default.
• W4309661662 hasConcept C2779615886 @default.
• W4309661662 hasConcept C2781190966 @default.
• W4309661662 hasConcept C2781433595 @default.
• W4309661662 hasConcept C509974204 @default.
• W4309661662 hasConcept C71924100 @default.
• W4309661662 hasConceptScore W4309661662C121608353 @default.
• W4309661662 hasConceptScore W4309661662C126322002 @default.
• W4309661662 hasConceptScore W4309661662C141071460 @default.
• W4309661662 hasConceptScore W4309661662C143998085 @default.
• W4309661662 hasConceptScore W4309661662C197934379 @default.
• W4309661662 hasConceptScore W4309661662C2776349617 @default.
• W4309661662 hasConceptScore W4309661662C2776694085 @default.
• W4309661662 hasConceptScore W4309661662C2777701055 @default.
• W4309661662 hasConceptScore W4309661662C2778105408 @default.
• W4309661662 hasConceptScore W4309661662C2778233292 @default.
• W4309661662 hasConceptScore W4309661662C2779159893 @default.
• W4309661662 hasConceptScore W4309661662C2779615886 @default.
• W4309661662 hasConceptScore W4309661662C2781190966 @default.
• W4309661662 hasConceptScore W4309661662C2781433595 @default.
• W4309661662 hasConceptScore W4309661662C509974204 @default.
• W4309661662 hasConceptScore W4309661662C71924100 @default.
• W4309661662 hasIssue "46" @default.
• W4309661662 hasLocation W43096616621 @default.
• W4309661662 hasLocation W43096616622 @default.
• W4309661662 hasLocation W43096616623 @default.
• W4309661662 hasLocation W43096616624 @default.
• W4309661662 hasOpenAccess W4309661662 @default.
• W4309661662 hasPrimaryLocation W43096616621 @default.
• W4309661662 hasRelatedWork W2013175739 @default.
• W4309661662 hasRelatedWork W2083578196 @default.
• W4309661662 hasRelatedWork W2600077404 @default.
• W4309661662 hasRelatedWork W2920319505 @default.
• W4309661662 hasRelatedWork W2991198231 @default.
• W4309661662 hasRelatedWork W3029627388 @default.
• W4309661662 hasRelatedWork W3116594146 @default.
• W4309661662 hasRelatedWork W3119980084 @default.

• next